缬沙坦对冠心病患者炎症指标及脂代谢水平的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the influence of Valsartan on inflammatory indexes and lipid metabolism levels in patients with coronary heart disease. Methods A total of 65 patients with coronary heart disease in Binhaiwan Central Hospital of Dongguan City from October 2017 to October 2018 were selected and divided into the control group (n=32)and the observation group (n=33) according to the random number table method. The control group was treated with Atorvastatin Calcium on the basis of conventional treatment, and the observation group was treated with Valsartan on the basis of the treatment of the control group. Inflammatory indexes, blood lipids, changes in the size of coronary plaque before and after treatment and adverse events within one year were observed in the two groups. Results After treatment,the levels of C-reactive protein, tumor necrosis factor-α, total cholesterol, triacylglycerol and low-density lipoprotein cholesterol in the observation group were lower than those in the control group, the levels of serum adiponectin and high-density lipoprotein cholesterol in the observation group were higher than those of the control group, the differences were statistically significant (P＜0.05). After treatment, the areas of fibrous plaques, lipid plaques, mixed plaques and calcified plaques in the observation group were smaller than those in the control group, and the differences were statistically significant (P＜0.05). The total incidence of adverse events in the observation group at one year after treatment was lower than that in the control group, and the difference was statistically significant (P＜0.05). Conclusion Valsartan can stabilize the inflammatory indicators of patients with coronary heart disease, improve lipid metabolism, reduce the area of coronary plaques, and reduce the occurrence of adverse events.

Key words： Valsartan Coronary heart disease Atorvastatin Calcium Blood lipid level

Received: 21 September 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I19/82

[1]	吴奕真，蔡震文.阿托伐他汀结合缬沙坦治疗冠心病的临床应用效果分析[J].心血管病防治知识（学术版），2019，9（11）：26-28.
[2]	任欣伟.缬沙坦联合美托洛尔对冠心病患者血液流变学及心肌微循环状态的影响[J].实用医药杂志，2018，35（9）：797-799.
[3]	于海港，岳欣峰.缬沙坦联合阿托伐他汀片治疗冠心病的效果[J].中国卫生标准管理，2019，10（15）：90-91.
[4]	洪敏，邱彬.阿托伐他汀联合缬沙坦治疗冠心病对冠状动脉病变及炎症状况改善分析[J].现代实用医学，2018，30（1）：38-40.
[5]	许三雄，程蕾群.缬沙坦对冠心病患者心功能和炎性因子水平的影响研究[J].心血管康复医学杂志，2020，29（1）：77-81.
[6]	佟彤.探讨阿托伐他汀联合缬沙坦对冠心病患者冠状动脉病变程度及对血清脂蛋白、C 反应蛋白水平的影响[J].北方药学，2018，15（5）：75-76.
[7]	张循明.冠心病诊断与治疗研究进展[J].中西医结合心血管病电子杂志，2019，7（9）：32，34.
[8]	曲鹏展.阿托伐他汀联合缬沙坦治疗冠心病的效果[J].河南医学研究，2018，27（24）：4512-4513.
[9]	姚翡，郁秋荣，龚叶，等.缬沙坦联合他汀类治疗糖尿病伴冠心病患者疗效及其对PPAR-γ 的影响[J].疑难病杂志，2018，17（7）：663-666.
[10]	袁美芳.阿托伐他汀联合缬沙坦对冠心病冠状动脉病变及炎症状况的影响[J].内蒙古医学杂志，2018，50（7）：819-820.
[11]	蔺红梅.他汀类药物治疗冠心病的临床应用分析[J].中国社区医师，2019，35（12）：32，35.
[12]	王永强.阿托伐他汀联合缬沙坦治疗冠心病合并糖尿病患者的临床价值分析[J].四川解剖学杂志，2019，27（2）：50-51.
[13]	王珊珊.缬沙坦联合PAS 疗法治疗高血压伴冠心病的疗效及对Hcy 的影响[J].中西医结合心脑血管病杂志，2018，16（10）：1385-1387.
[14]	石辉进.阿托伐他汀钙对高血压冠心病患者IMT 厚度及血脂和心功能的影响[J].河北医药，2018，40（11）：1733-1735.
[15]	李萍，王少敏，陈俊清，等.缬沙坦联合他汀类药物治疗冠心病的效果分析[J].国际检验医学杂志，2019，40（4）：427-430，434.